These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. pH-triggered drug release from biodegradable microwells for oral drug delivery. Nielsen LH; Nagstrup J; Gordon S; Keller SS; Østergaard J; Rades T; Müllertz A; Boisen A Biomed Microdevices; 2015; 17(3):9958. PubMed ID: 25981751 [TBL] [Abstract][Full Text] [Related]
3. Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. Nielsen LH; Rades T; Müllertz A Int J Pharm; 2015 Jul; 490(1-2):334-40. PubMed ID: 26026252 [TBL] [Abstract][Full Text] [Related]
4. From concept to in vivo testing: Microcontainers for oral drug delivery. Mazzoni C; Tentor F; Strindberg SA; Nielsen LH; Keller SS; Alstrøm TS; Gundlach C; Müllertz A; Marizza P; Boisen A J Control Release; 2017 Dec; 268():343-351. PubMed ID: 29054373 [TBL] [Abstract][Full Text] [Related]
5. Ex vivo intestinal perfusion model for investigating mucoadhesion of microcontainers. Dalskov Mosgaard M; Strindberg S; Abid Z; Singh Petersen R; Højlund Eklund Thamdrup L; Joukainen Andersen A; Sylvest Keller S; Müllertz A; Hagner Nielsen L; Boisen A Int J Pharm; 2019 Oct; 570():118658. PubMed ID: 31491485 [TBL] [Abstract][Full Text] [Related]
6. Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading. Li P; Tan A; Prestidge CA; Nielsen HM; Müllertz A Int J Pharm; 2014 Dec; 477(1-2):390-8. PubMed ID: 25455781 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison of microcontainers and microspheres for oral drug delivery. Christfort JF; Strindberg S; Al-Khalili S; Bar-Shalom D; Boisen A; Nielsen LH; Müllertz A Int J Pharm; 2021 May; 600():120516. PubMed ID: 33775722 [TBL] [Abstract][Full Text] [Related]
8. Microcontainers for protection of oral vaccines, in vitro and in vivo evaluation. von Halling Laier C; Gibson B; Moreno JAS; Rades T; Hook S; Nielsen LH; Boisen A J Control Release; 2019 Jan; 294():91-101. PubMed ID: 30550938 [TBL] [Abstract][Full Text] [Related]
9. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
10. Biodegradable microcontainers - towards real life applications of microfabricated systems for oral drug delivery. Abid Z; Strindberg S; Javed MM; Mazzoni C; Vaut L; Nielsen LH; Gundlach C; Petersen RS; Müllertz A; Boisen A; Keller SS Lab Chip; 2019 Sep; 19(17):2905-2914. PubMed ID: 31367713 [TBL] [Abstract][Full Text] [Related]
11. Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. Terao T; Matsuda K; Shouji H J Pharm Pharmacol; 2001 Apr; 53(4):433-40. PubMed ID: 11341359 [TBL] [Abstract][Full Text] [Related]
12. Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide. Meka L; Kesavan B; Kalamata VN; Eaga CM; Bandari S; Vobalaboina V; Yamsani MR J Pharm Sci; 2009 Jun; 98(6):2122-32. PubMed ID: 19009598 [TBL] [Abstract][Full Text] [Related]
13. Supersaturated polymeric micelles for oral cyclosporine A delivery. Yu H; Xia D; Zhu Q; Zhu C; Chen D; Gan Y Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1325-36. PubMed ID: 23954511 [TBL] [Abstract][Full Text] [Related]
14. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Zhang Y; Wu X; Meng L; Zhang Y; Ai R; Qi N; He H; Xu H; Tang X Int J Pharm; 2012 Oct; 436(1-2):341-50. PubMed ID: 22766443 [TBL] [Abstract][Full Text] [Related]
15. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449 [TBL] [Abstract][Full Text] [Related]
17. Intravenous delivery of furosemide using lipid-based versus polymer-based nanocapsules: Kamel YN; El-Marakby EM; Gad HA Pharm Dev Technol; 2024 Sep; 29(7):738-750. PubMed ID: 39105766 [TBL] [Abstract][Full Text] [Related]
18. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Zvonar A; Berginc K; Kristl A; Gasperlin M Int J Pharm; 2010 Mar; 388(1-2):151-8. PubMed ID: 20060454 [TBL] [Abstract][Full Text] [Related]
19. Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations. Vlachou M; Siamidi A; Dotsikas Y Curr Drug Deliv; 2019; 16(10):931-939. PubMed ID: 31663479 [TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. Nkansah P; Antipas A; Lu Y; Varma M; Rotter C; Rago B; El-Kattan A; Taylor G; Rubio M; Litchfield J J Control Release; 2013 Jul; 169(1-2):150-61. PubMed ID: 23570985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]